{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.7.2', 'Day 1/Baseline', 'Perform predose Baseline efficacy assessments (CAS, Clinical Measures of Severity', 'including proptosis, diplopia and motility restriction proptosis, CAS, Clinical', 'Measures of Severity including motility restriction). Proptosis and CAS may not decrease', '> 2 mm/points in the study eye from Screening to be eligible for enrollment.', '9.5.7.6 Week 6', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', '9.5.7.8', 'Week 12', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', '9.5.7.9 Week 15', 'Collect predose urine sample for urinalysis and also a pregnancy test for females of', 'childbearing potential; the pregnancy test must be negative for the subject to receive', 'study drug.', '9.5.7.10 Week 18', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', '9.5.7.12 Week 24', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Subjects who are proptosis non-responders will be offered the opportunity to receive up to 8', 'additional infusions of teprotumumab in an open-label extension study, HZNP-TEP-302.', '9.5.7.13 Week 28', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', '9.5.7.14 Week 36', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 18 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.7.15 Week 48', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', '9.5.7.16 Week 60', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', '9.5.7.17 Week 72', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Subjects will be discharged from the study center after all of the procedures have been', 'completed.', 'The end of the trial is defined as the date of the last visit of the last subject undergoing the trial.', '9.5.7.18 Week 96 - Follow-Up Contact', 'Subjects who complete the Week 72 Visit will be contacted 6 months later via phone or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', '9.5.7.19 Week 120 - Follow-Up Contact', 'Subjects who complete the Week 72 Visit will be contacted 12 months later via phone or', 'email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'The end of the trial is defined as the date of the last subject contact at Week 120.', '9.6.1.2 Secondary Enppoints', 'Secondary Enppoints (analyzed hierarchically):', '4.', 'Diplopia responder rate (percentage of subjects with baseline diplopia > 0 in study', 'eve who have a reduction of > 1 grade with no corresponding deterioration 1', 'grade worsening in the fellow eye) at Week 24.', '5.4.', 'Mean change from Baseline to Week 24 in the GO-QoL questionnaire overall score.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 19 of 117']\n\n###\n\n", "completion": "END"}